Abortion Back In Supreme Court Showdown In Election Year, Opponents Challenge Mifepristone Safety
Abortion Back In Supreme Court Showdown In Election Year, Opponents Challenge Mifepristone Safety
The Supreme Court is scheduled to hear arguments on Tuesday regarding the overturning of the 1973 Roe v. Wade ruling, which had established a constitutional right to abortion.
最高法院定於週二聽取有關推翻1973年羅伊訴韋德案裁決的辯論，該裁決確立了墮胎的憲法權利。
Abortion opponents are making a fervent plea to the U.S. Supreme Court, aiming to curtail access to the abortion pill, mifepristone, a drug employed in over half of all abortions within the U.S.
反對墮胎的人正在向美國最高法院強烈呼籲，旨在限制獲得墮胎藥米非司酮的機會，這種藥物用於美國一半以上的墮胎中。
Their argument hinges on studies conducted by Gynuity Health Projects, which they claim demonstrate the pill's alleged dangers despite its decades-old regulatory approval.
他們的論點取決於Gynuity Health Projects進行的研究，他們聲稱儘管該藥已獲得監管部門的批准數十年，但仍存在所謂的危險。
The studies conducted by Gynuity Health Projects, which evaluate the feasibility and safety of providing abortion drugs via videoconference and mail, have been cited by plaintiffs challenging the current FDA regulations on mifepristone.
原告援引了Gynuity Health Projects進行的研究，這些研究評估了通過視頻會議和郵件提供墮胎藥物的可行性和安全性，質疑美國食品藥品管理局關於米非司酮的現行規定。
They assert that these studies reveal alarming rates of emergency room visits and increased risks for patients, Reuters noted, urging the court to roll back access to the medication.
路透社指出，他們斷言，這些研究顯示急診室就診率驚人，患者風險增加，並敦促法院減少獲得藥物的機會。
President Joe Biden's administration is contesting a lower court's decision to ease FDA restrictions on mifepristone, highlighting the broader implications such a ruling could have on federal regulatory authority over drug safety.
喬·拜登總統的政府正在對下級法院放寬美國食品藥品管理局對米非司酮限制的決定提出異議，強調該裁決可能對聯邦藥品安全監管機構產生的更廣泛影響。
The plaintiffs argue that the FDA's decisions to relax mifepristone restrictions have jeopardized women's safety, questioning the agency's judgment and the reliability of the studies in their filings to the Supreme Court.
原告辯稱，美國食品藥品管理局放鬆米非司酮限制的決定危及了女性的安全，他們質疑該機構的判決以及向最高法院提交的文件中研究的可靠性。
Following the Dobbs v. Jackson Women's Health Organization ruling, which stripped federal protections for abortion, the issue has returned to the forefront of the court's agenda.
繼多布斯訴傑克遜婦女健康組織案的裁決剝奪了聯邦對墮胎的保護之後，這個問題又回到了法院議程的重中之重。
Despite abortion bans in about one-third of states, the accessibility of mifepristone, particularly through mail services, has increased, leading to no significant overall decline in abortions.
儘管約三分之一的州禁止墮胎，但米非司酮的可及性，尤其是通過郵寄服務獲得的途徑有所增加，導致墮胎率總體上沒有顯著下降。
This trend has frustrated Republican politicians and anti-abortion advocates who anticipated a decrease following the potential overturning of Roe v. Wade.
這種趨勢令共和黨政客和反墮胎倡導者感到沮喪，他們預計在羅伊訴韋德案可能被推翻後，墮胎人數會減少。
Medication abortions constitute nearly two-thirds of all terminations, with approximately 150,000 more cases in 2023 compared to pre-Dobbs levels in 2020, the Wall Street Journal noted, citing the Guttmacher Institute.
《華爾街日報》援引古特馬赫研究所的話指出，藥物流產佔所有終止人數的近三分之二，與2020年多布斯之前的水平相比，2023年的病例增加了約15萬例。
The forthcoming ruling from the high court, anticipated by July, could significantly impact election dynamics occurring amidst the election season.
預計高等法院將於7月作出裁決，這可能會對選舉季節期間的選舉動態產生重大影響。
This ruling has the potential to influence various races across the ballot spectrum, coinciding with abortion's prominence as a pivotal political issue following the Dobbs case.
該裁決有可能影響選民範圍內的各種競選，恰逢墮胎在多布斯案之後作爲關鍵政治問題佔據突出地位。
Earlier this month, Pharmacy chain giants CVS Health Corp (NYSE:CVS) and Walgreens Boots Alliance Inc (NASDAQ:WBA) announced plans to dispense the abortion pill mifepristone, following FDA guidelines issued last year.
本月早些時候，連鎖藥房巨頭CVS Health Corp（紐約證券交易所代碼：CVS）和Walgreens Boots Alliance Inc（納斯達克股票代碼：WBA）宣佈了根據美國食品藥品管理局去年發佈的指導方針分發墮胎藥米非司酮的計劃。
Both pharmacy chains confirmed their certification and intend to introduce mifepristone in stores, starting with a phased rollout in select states.
兩家連鎖藥房都確認了認證，並打算在門店推出米非司酮，首先在部分州分階段推出。
Image Via Shutterstock
圖片來自 Shutterstock
譯文內容由第三人軟體翻譯。